Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2018 | CAR T-cells in lymphoma: where are we now?

CAR T-cells are a hot topic right now, with huge potential for transforming the treatment of various hematological malignancies, including lymphoma. Here, David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, chairs a discussion on the current landscape of CAR T-cell therapy in lymphoma at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. They are joined by James Kochenderfer, MD, from the National Cancer Institute, Rockville, MD, Steve Schuster, MD, from the University of Pensylvania, Philadelphia, PA, and William Go, MD, PhD, from Kite Pharma Inc., Santa Monica, CA. Along with an overview of the state of CAR T-cell therapy today, the group discuss the current standards for treatment and the avoidance of toxicities, such as neurotoxicity and cytokine release syndrome, and specific targets for this cellular therapy.